LENZ Therapeutics, Inc. is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Solana Beach, CA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $19 million and a loss of $82 million (its filed statements).
Pre-revenue companyBiological Products, (No Diagnostic Substances)Solana Beach, CAfilings since 20214 of 9 filed, 5 estimated
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a pre-revenue company: no meaningful revenue on file yet (industry code 2836), so it is read as a pre-revenue company; the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 5.6 out of ten, 4 of 9 metrics filed and 5 estimated: past 6.2 out of ten, present 6.2 out of ten, future 4.8 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
Surviving crises (past): 5.3 out of ten. 1 warning event since 2021; the latest 2024-03-22. 53rd percentile among 159 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Track record (past): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 20 of 100 (family median). 50th percentile among 103 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Shareholder treatment (past): 8.5 out of ten. CrossAssetData estimate 8.5/10, confidence 35 of 100 (one part). 85th percentile among 146 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Financial health (present): 5.5 out of ten. ROE -29%: lost 29¢ per shareholder dollar. Leverage 7%: owes 7¢ per asset dollar. 55th percentile among 147 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Industry position (present): 4.5 out of ten. bottom 45% of 102 in its family; net margin -430.3%. 45th percentile among 102 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Leadership (present): 8.3 out of ten. CrossAssetData estimate 8.3/10, confidence 35 of 100 (one part). 83rd percentile among 139 sector filers. A CrossAssetData estimate, not a filed reading: one part, confidence 35 of 100; a filing that carries the missing parts replaces this estimate with the filed reading.
Room to expand (future): 4.3 out of ten. bottom 43% of 92 in its family for room to expand. 43rd percentile among 92 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
Growth drivers (future): 4.9 out of ten. CrossAssetData estimate 4.9/10, confidence 20 of 100 (family median). 50th percentile among 101 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
Expectations vs reality (future): 5.1 out of ten. CrossAssetData estimate 5.1/10, confidence 20 of 100 (family median). 50th percentile among 73 sector filers. A CrossAssetData estimate, not a filed reading: family median, confidence 20 of 100; its next annual report on file with the inputs replaces this estimate with the filed reading.
The filing record
Newest annual report: Form 10-K filed 2026-03-24 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-11 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-11 (on EDGAR). Newest filing: Form SCHEDULE 13G/A, 2026-09-08. Filings on record since 2021. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: License 92%, Product 8%. As tagged in its annual report (Form 10-K, filed 2026-03-24).
Who runs it
Schimmelpennink, Evert B. (President, CEO and Secretary); Chevallard, Daniel R. (Chief Financial Officer); Odrich, Marc (Chief Medical Officer); Olsson, Shawn (Chief Commercial Officer); Drapkin, Kimberlee C (director); George, Jeffrey P. (director); Guerard, Frederic (director); Kolchinsky, Peter (director); Mccollum, James W (director); Ra, Capital Healthcare Fund Lp (director); and 5 more. 15 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-09-30.
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.